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The oncogenic potential and activation of human  epidermal 
growth factor receptor 2 (HER2) has been well established in 
several human malignancies, most notably in breast and gas-
tric/gastroesophageal junction (GEJ) carcinomas. The primary 
mechanism of the HER2 activation in these cancers is HER2 
gene amplification that leads to the complete HER2 protein 
overexpression on the cellular membrane [1,2]. In recent years, 
other genomic alterations of HER2 have also been recognized 
leading to protein activation among which HER2 gene muta-
tions represent the most important form [3]. HER2 mutations 
are usually of activating type and the majority of them are seen 
without concurrent HER2 gene amplification [3-5]. The high-
est prevalence (>10%) of HER2 mutations has been observed 
in prostate neuroendocrine carcinomas, metastatic cutane-
ous squamous cell carcinomas and urothelial bladder carci-
noma. Additionally, HER2 mutations have also been reported 
in common cancers such as pulmonary, colorectal and breast 
cancers, indicating a potential for HER2-directed therapies in 
these cancers [4,6-12]. HER2 mutations are enriched in certain 
specific histological subtypes, for instance in invasive lobular 
carcinoma of the breast (5-18%) [13-15] and in ~2-3% of pul-
monary adenocarcinomas  [16-21]. Recently, HER2 mutations 
were reported to occur more frequently in microsatellite insta-
ble (MSI-H) colorectal carcinomas than in microsatellite sta-
ble (MSS) cases [10, 11]. HER2 genomic alterations were also 
enriched in RAS wild-type and anti-EGFR therapy resistant 
colorectal carcinomas [22]. Studies in non-small cell lung carci-
nomas (NSCLC) revealed mutations affecting predominantly 
exon 20 and were seen without amplification of HER2 gene. In 
addition, HER2 mutations were mutually exclusive with other 
common oncogenic drivers in NSCLC. In contrast to epider-
mal growth factor receptor (EGFR) mutations, the frequency 
of HER2 mutations appear to be similar between Asian and 
Caucasian populations [16].
The anti-HER2 antibody trastuzumab has been a corner-
stone and effective therapy in treatment of HER2-positive 
breast and gastric cancers. However, the number of approved 
anti-HER2 therapeutic agents has been markedly expanded 
in recent years, with the addition of tyrosine kinase inhibi-
tors (lapatinib, neratinib, tucatinib), antibodies (pertuzumab), 
and antibody-drug conjugates [ado-trastuzumab emtansine 
(T-DM1)] and trastuzumab deruxtecan (DS-8201)] (summa-
rized in Table 1) [3]. Used alone or in combination with other 
targeting agents or conventional chemotherapeutics, these 
anti-HER2 agents have remarkably improved the outcome of 
patients with HER2-positive breast cancer [23, 24].
One of the most recent antibody-drug conjugates (ADC) 
against HER2 is trastuzumab deruxtecan (Enhertu; DS-8201; 
AstraZeneca and Daiichi Sankyo Company, Limited 
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Abstract
Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to 
the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 
gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have 
become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of 
human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating 
HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensi-
tivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan 
in patients with non-squamous non-small cell lung carcinoma.
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(Daiichi Sankyo). It is composed of an anti-HER2 antibody 
(trastuzumab), a cleavable tetrapeptide-based linker, and 
a cytotoxic topoisomerase I (TOP1) inhibitor (“payload”) 
(Table 1). Previously, it was published that TOP1 was overex-
pressed in 63% of all invasive breast carcinomas [25]. Enhertu 
appears to exhibit a higher drug-to-antibody ratio than 
another anti-HER2 ADC trastuzumab emtansine (Kadsyla) 
(approximately 8 vs. 3-4) while retaining a favorable phar-
macokinetic characteristics [26]. In contrast to trastuzumab 
emtansine, trastuzumab deruxtecan has a released payload 
that may easily cross the cell membrane, which potentially 
allows for potent cytotoxic effects on cancer cells regardless 
of target expression [27-29]. In addition, the released payload 
has a substantially shorter half-life, which may minimize 
systemic exposure and potential side effects [30]. In breast 
cancer, trastuzumab deruxtecan has been shown to exhibit 
a durable therapeutic activity in a population of heavily pre-
treated patients (≥2 prior anti–HER2-based regimens) with 
advanced HER2-positive breast cancer  [31]. This phase 2 
study (II DESTINY-Breast01 trial) revealed that a response 
to trastuzumab deruxtecan was achieved in 60.9% of the 
patients of which 6% had a complete response (CR) while 
54.9% of patients had a partial response [31]. The preliminary 
data from the II DESTINY-Breast01 trial were presented at 
the San Antonio 2019 meeting  [32] and led to the acceler-
ated approval by the Food and Drug Administration (FDA) 
in December 2019.
The results from another ongoing trial named Phase II 
DESTINY-Lung01 trial have just been presented at the 2020 
American Society of Clinical Oncology (ASCO) Virtual 
Scientific Program [33]. This trial showed that trastuzumab 
deruxtecan also achieved a clinically significant tumor response 
in patients with HER2-mutant advanced non-squamous 
NSCLC whose disease had progressed following one or more 
previous systemic therapies (chemotherapy or immunotherapy 
with immune checkpoint inhibitors against PD-1/PD-L1) [33]. 
The confirmed objective response rate (ORR) was achieved in 
61.9% of patients treated with trastuzumab deruxtecan mono-
therapy (6.4mg/kg). A disease control rate (DCR) of 90.5% with 
a median progression-free survival (PFS) of 14 months were 
remarkable achievements in this study. However, other relevant 
endpoints such as a median duration of response and overall sur-
vival (OS) have not been reached at the time of data cut-off [33]. 
Nevertheless, these encouraging results, after many failed trials 
and extensive research on HER2 in NSCLC [34-36], may pave a 
new way for the treatment of a small subset of NSCLC harboring 
HER2 gene mutations. Interestingly, for the predictive purposes 
HER2-overexpressing non-squamous NSCLC (defined as scores 
2+ and 3+ by immunohistochemistry/IHC/) or non-squamous 
NSCLC harboring a HER2-activating mutation, were used in 
this trial. From the provided abstract [33], it is not clear whether 
the differences in a treatment response were observed between 
HER2-mutant NSCLC and HER2-overexpressing NSCLC (2+ 
and 3+ scores by IHC). In contrast, an ongoing, phase II trial 
with trastuzumab deruxtecan in advanced gastric/GEJ carcino-
mas (DESTINY-Gastric01) enrolled only those patients whose 
cancers were HER2-positive (Score 3+ by IHC or 2+ IHC with 
confirmatory HER2 amplification by in situ hybridization assay). 
A clinical trial on NSCLC with ADC trastuzumab emtansine 
(T-DM1) reported responses to the targeted drug only in IHC 3+ 
NSCLC while no responses were found in 2+ NSCLC cases [37]. 
It is well-known that HER2 status assessed by IHC (particularly 
score 2+) is not an optimal approach for selection of the patients 
having a mutant HER2 cancer as recently shown in case of col-
orectal carcinoma [38]. Apart from the well-documented exam-
ples of mutation-specific IHC antibodies (e.g. BRAF p.V600E, 
TABLE 1. Overview of the anti-HER2 agents that have been approved in breast and gastric cancers
Anti-HER2 agent Structure Mechanism of action Approved indications#
Trastuzumab Monoclonal antibody Immune-mediated response causing internalization and downregulation of HER2
HER2+ breast cancer
HER+ gastric cancer
Pertuzumab Monoclonal antibody Prevents HER2-HER3 dimerization (combined with trastuzumab and docetaxel)
HER2+ breast cancer
Trastuzumab emtansine 
(ado-trastuzumab emtansine)
Antibody-drug conjugate 
(ADC)
Trastuzumab and DM1 (cytotoxic maytansinoid); DM1 binds 
microtubules and inhibits cell division in the tumor cells
HER2+ breast cancer
Trastuzumab deruxtecan 
(DS-8201)
Antibody-drug conjugate 
(ADC)
Trastuzumab and a topoisomerase I inhibitor conjugate 
deruxtecan
HER2+ breast cancer*
Lapatinib Dual tyrosine kinase inhibitor Blocks EGFR/HER2 protein kinase activity ER+/EGFR+/HER2+ breast cancer
Neratinib Dual tyrosine kinase inhibitor Blocks EGFR/HER2 activity by covalently binding with a cysteine side chain in those receptors
HER2+ breast cancer
Tucatinib Tyrosine kinase inhibitor Highly selective inhibitor of the kinase domain of HER2 receptor
HER2+ breast cancer**
ER = Estrogen receptor; EGFR = Epidermal growth factor receptor; HER2 = Human epidermal growth receptor 2
#Only approved drugs are provided in the list.
*Breakthrough Therapy Designation (BTD) has been granted for this drug in May 2020 for the treatment of advanced/metastatic gastric/GEJ 
carcinomas and non-small cell lung carcinomas harboring HER2 gene mutations. Trastuzumab deruxtecan (DS-8201) has been approved by 
FDA for metastatic HER2+ breast cancer in December 2019. 
**The approval for this drug was granted by FDA in April 2020 and was based on the clinical trial HER2CLIMB, ClinicalTrials.gov number, 
NCT02614794 [54]. 
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IDH1 p.R132H, or H3K27M), which tend to correlate well with 
the specific mutations [39], IHC antibodies that target specific 
proteins may lack correlation with the DNA-level mutational 
events. There are several possible reasons including the fact that 
the mutation may not result in (increased) protein expression 
(e.g. due to transcriptomic silencing of genetic variant or dis-
cordance between the DNA alterations and RNA expression)
[40], hence IHC may be consequently negative/low positive; 
another possibility is that the antibody may target a specific epi-
tope that may or may not be altered by the mutation. In case of 
trastuzumab deruxtecan, another important therapeutic target 
is TOP1, which is inhibited by the ADC payload deruxtecan. 
TOP1 is an enzyme with an active role in DNA function by the 
cleavage one of the two backbones in double-stranded DNA 
enabling the double helix to be untwisted [41]. TOP1 status has 
been extensively studied by immunohistochemistry, most nota-
bly in colorectal carcinoma where it has been shown to predict 
a response to irinotecan-based chemotherapy [42,43]. It is well-
known that irinotecan may reversibly stabilize the TOP1 cleav-
able complex, resulting in single-strand DNA breaks and ulti-
mate cell death  [44]. In addition, a high TOP1 expression has 
also been demonstrated in several other cancers, including small 
cell lung, gastric/gastroesophageal, esophageal, thymic, anal, 
breast, prostate and poorly differentiated neuroendocrine carci-
nomas [25]. The same study as well as several other studies also 
revealed a common TOP1 overexpression in NSCLC [45,46]. 
Another ADC sacituzumab govitecan-hziy (TRODELVY, 
Immunomedics, Inc.) was recently approved for the patients 
with metastatic triple-negative breast cancer (TNBC). It rep-
resents an anti-Trop-2 (=trophoblast cell-surface antigen 2) 
ADC and contains irinotecan metabolite, SN-38 that is con-
jugated to a humanized anti-TROP-2 antibody (sacituzumab 
govitecan)  [47]. Although both Trop-2 and TOP1 expression 
have been well-documented in various cancers including breast 
cancer [25,48-52], predictive testing was not conducted in this 
trial (IMMU-132-01 (NCT 01631552) clinical trial [53].
In short, recent data indicate that HER2 mutations may be 
successfully targeted with the available anti-HER2 treatment 
modalities. ADC such as trastuzumab deruxtecan represent novel 
promising therapeutic means for the patients with advanced 
non-squamous NSCLC. Despite the remarkable achievements, 
we believe that further efforts should be made to optimize the 
treatment with these ADC where molecular targets are well char-
acterized and may be easily assessed prior to targeted treatments.
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